Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Conventional medical treatment · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Mononuclear cells from autologous bone marrow | EXPERIMENTAL | Mononuclear bone marrow cells autologous intracoronary |
| Conventional medical treatment | ACTIVE_COMPARATOR | Conventional medical treatment |
| Name | Type | Description |
|---|---|---|
| Mononuclear cells from autologous bone marrow | OTHER | Mononuclear bone marrow cells autologous intracoronary |
| Conventional medical treatment | DRUG | - |
Inclusion Criteria: 1. Patients who give their informed consent to participate in this clinical trial. 2. Patients of both sexes with atherosclerotic coronary artery disease and chronic occlusions that recanalization has been achieved successfully implanted medicated stents, and in which neverthele...
Conventional medical treatment is a small molecule being studied for Coronary Atherosclerosis and Other Heart Disease. It is currently in Phase 2 clinical development as an active-controlled therapy. The treatment is being evaluated in patients with chronic coronary occlusion and ventricular dysfunction who have previously undergone revascularization.
Conventional medical treatment is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded under the ticker DSGN. The company is conducting clinical research in the cardiovascular therapeutic area, with the drug currently in Phase 2 development for Coronary Atherosclerosis and Other Heart Disease.
Conventional medical treatment is in Phase 2 clinical development. It is an investigational therapy for Coronary Atherosclerosis and Other Heart Disease and has not been approved by regulatory authorities. The drug is being evaluated in a completed Phase 2 clinical trial with 28 participants.
Conventional medical treatment has one completed clinical trial, NCT02022514, titled "Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized." This Phase 2 study enrolled 28 participants in Spain and included patients aged 18 years and older.
Conventional medical treatment is the active-controlled comparator in a clinical trial that evaluates intracoronary infusion of autologous bone marrow mononuclear cells. The trial compares the investigational cell therapy against conventional medical treatment in patients with chronic coronary occlusion and ventricular dysfunction.